Optimal clinical use of blood and blood components is at the heart of the objectives of clinicians and hospitals in Europe and elsewhere to ensure that safe blood-derived therapeutic products are given to the patients in need, at the right time, in adequate doses.
This symposium addresses the optimal clinical use of clotting factors and platelets, notably the expanding use of novel haemophilia products and of pathogen-inactivated platelets.
It was co-organised by the Ludwig Maximilians University (LMU) of Munich, the Paul-Ehrlich-Institut (PEI), and the EDQM, Council of Europe.
The aim of the Kreuth conferences is to be not just another scientific meeting with presentations of the latest cutting-edge scientific findings, but to provide a platform for exchanging and discussing current clinical practices and projections of future developments across the Council of Europe member states and to formulate useful recommendations on the optimal use of components derived from human blood and plasma.
Target audience
The conference is of interest to scientists in the biology or biochemistry of platelets, to physicians involved in the treatment of bleeding and thrombotic diseases, and those working in the pharmaceutical / biotechnology companies developing new blood-derived therapeutics products.
Materials
- "Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates", Haemophilia (2017), 1–6
- Watch the EHC’s video on European recommendations for the treatment of haemophilia
Other Events / Training Sessions
- Symposium Proceedings: Optimal use of clotting factors and immunoglobulins proceedings (2013)
- Conference: Keeping up with Reality and Quality: A Challenge for European Blood Establishments
